Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Scientists at Toronto General Hospital Research Institute (TGHRI) have developed a new system that could significantly advance the development of cell-based therapies for treating heart attacks, a leading cause of death in Canada.
Heart attacks occur when the blood vessels that supply blood to the heart are blocked, leading to tissue damage. These damaged regions can often develop scar tissue and lose the ability to pump blood properly.
Researchers at UHN and elsewhere have developed methods to generate functional heart cells in the lab that, in theory, could be used to repair these damaged regions.
"While the idea of using cell replacement therapy to treat heart disease has been around for over 20 years, we still do not have an approved cell therapy," explains TGHRI Scientist Dr.
Sara Vasconcelos, lead author of the work published in
Science Translational Medicine.
"One key reason for the lack of effective cell therapies for heart disease is that we have yet to optimize systems to support survival of transplanted heart cells."
To address this clinical challenge, Dr. Vasconcelos's group has developed a lab-engineered system in which ready-made blood vessels harvested from fat tissue are implanted along with heart muscle cells.
The team found that using these blood vessels increases the survival of the transplanted heart cells more than six-fold in an experimental model of heart disease.
Major advancement in the field
"Our studies show that the blood vessels increase the flow of nutrients to the transplanted cells and produce factors that support cell growth, which enhances their survival," says Dr. Vasconcelos. Transplanting the cells with the ready-made blood vessels also improves heart function in the same experimental model.
The researchers discovered that the transplanted vessels constitute the bulk of the vessels within the grafts, which is a major advancement in the field. This is in stark contrast to other known approaches for introducing blood vessels, in which most transplanted cells disappear within a few days.
There are currently no other studies describing effective retention of the transplanted blood vessel cells in the heart.
The findings of the study represent a step forward in the field and could pave the way for new and effective cell-based therapies for heart disease.
This work was supported by the Canadian Institutes of Health Research, the Institute of Circulatory and Respiratory Health. G Keller holds a Tier 1 Canada Research Chair in Embryonic Stem Cell Biology. RK Li holds a Tier 1 Canada Research Chair in Cardiac Regeneration.